Translational Lung Cancer Research

Journal Title：Translational Lung Cancer Research

Translational Lung Cancer Research(TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) is an international, peer-reviewed, open-access journal, which was founded in March 2012. TLCR is indexed by PubMed/PubMed Central and the Chemical Abstracts Service (CAS) Databases. It is published quarterly the first year, and published bimonthly since February 2013. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer. Specific areas of its interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer.

转化肺癌研究（TLCR，Transl Lung Cancer Res，印刷 ISSN 2218-6751；在线 ISSN 2226-4477）是一本国际性、同行评审、开放获取期刊，创刊于 2012 年 3 月。TLCR 被 PubMed/PubMed Central 和化学文摘服务 (CAS) 数据库收录。该期刊第一年每季度出版一次，自 2013 年 2 月起每两个月出版一次。它提供有关肺癌预防、早期检测、诊断和治疗的实用最新信息。其关注的特定领域包括但不限于多模态治疗、标记物、成像、肿瘤生物学、病理学、化学预防和与肺癌相关的技术进步。

Translational Lung Cancer Research创刊于2012年，由Society for Translational Medicine (STM)出版商出版，收稿方向涵盖Medicine - Oncology全领域，此刊是该细分领域中属于非常不错的SCI期刊，在行业细分领域中学术影响力较大，专业度认可很高，所以对原创文章要求创新性较高，如果您的文章质量很高，可以尝试。平均审稿速度 In-house review: 1-3 weeks; External peer review: 1-3 months; Publication Ahead of Print: within 1 month after being accepted ，影响因子指数4，该期刊近期没有被列入国际期刊预警名单，广大学者值得一试。